RAD51 Inhibitor B02
Based on 16 publication(s) in Google Scholar
RAD51 Inhibitor B02 (B02) is an inhibitor of human RAD51 with an IC50 of 27.4 μM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.89%
- CAS No.: 1290541-46-6
- Formule: C22H17N3O
- Masse moléculaire:339.39
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) RAD51 Inhibitor B02
More- Cell. 2025 Jun 26;188(13):3405-3421.e27. [Abstract]
- Drug Resist Updat. 2025 May:80:101214. [Abstract]
- Nat Commun. 2025 Jan 27;16(1):1077. [Abstract]
- Cancer Lett. 2023 Apr 1:558:216092. [Abstract]
- Cancer Lett. 2021 Nov 1:520:361-373. [Abstract]
- Oncogene. 2023 Apr;42(17):1374-1391. [Abstract]
- Mol Cancer Ther. 2026 Jul 15:10.1158/1535-7163.MCT-26-0182.
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Cancers (Basel). 2021 Apr 21;13(9):1998. [Abstract]
- Cell Signal. 2023 Jun:106:110639. [Abstract]
- Discov Oncol. 2025 Jul 12;16(1):1320. [Abstract]
- J Cancer Res Ther. 2020;16(2):215-221. [Abstract]
- bioRxiv. 2025 Jun 17:2025.06.16.659978. [Abstract]
- Northwestern University. 2024.
- bioRxiv. 2023 Dec 19.
- Res Sq. 2023 Apr 6:rs.3.rs-2688694. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
IF
-
WB
-
IF
Activité biologique
IC50: 27.4 μM (hRAD51)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BT-549 | IC50 |
35.4 μM
Compound: 9; B02
|
Cytotoxicity against human BT549 cells assessed as decrease in cell viability after 120 hrs by MTS assay
Cytotoxicity against human BT549 cells assessed as decrease in cell viability after 120 hrs by MTS assay
|
[PMID: 28545975] |
| HCC1937 | IC50 |
89.1 μM
Compound: 9; B02
|
Cytotoxicity against human HCC1937 cells assessed as decrease in cell viability after 120 hrs by MTS assay
Cytotoxicity against human HCC1937 cells assessed as decrease in cell viability after 120 hrs by MTS assay
|
[PMID: 28545975] |
| Hs-578T | IC50 |
9.6 μM
Compound: 9; B02
|
Cytotoxicity against human Hs578T cells assessed as decrease in cell viability after 120 hrs by MTS assay
Cytotoxicity against human Hs578T cells assessed as decrease in cell viability after 120 hrs by MTS assay
|
[PMID: 28545975] |
| MCF-10A | IC50 |
47.7 μM
Compound: 9; B02
|
Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 120 hrs by MTS assay
Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 120 hrs by MTS assay
|
[PMID: 28545975] |
| MDA-MB-231 | IC50 |
11.1 μM
Compound: 9; B02
|
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 120 hrs by MTS assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 120 hrs by MTS assay
|
[PMID: 28545975] |
| MDA-MB-436 | IC50 |
5.7 μM
Compound: 9; B02
|
Cytotoxicity against human MDA-MB-436 cells assessed as decrease in cell viability after 120 hrs by MTS assay
Cytotoxicity against human MDA-MB-436 cells assessed as decrease in cell viability after 120 hrs by MTS assay
|
[PMID: 28545975] |
| MDA-MB-468 | IC50 |
10.2 μM
Compound: 9; B02
|
Cytotoxicity against human MDA-MB-468 cells assessed as decrease in cell viability after 120 hrs by MTS assay
Cytotoxicity against human MDA-MB-468 cells assessed as decrease in cell viability after 120 hrs by MTS assay
|
[PMID: 28545975] |
| SUM-159-PT | IC50 |
84.1 μM
Compound: 9; B02
|
Cytotoxicity against human SUM159PT cells assessed as decrease in cell viability after 120 hrs by MTS assay
Cytotoxicity against human SUM159PT cells assessed as decrease in cell viability after 120 hrs by MTS assay
|
[PMID: 28545975] |
RAD51 Inhibitor B02 specifically inhibits human RAD51 (IC50=27.4 μM), but not its E. coli homologue RecA (IC50>250 μM)[1]. The combination of B02 with cisplatin has the strongest killing effect on the human breast cancer cells MDA-MB-231[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1290541-46-6
-
Appearance Solid
-
Masse moléculaire 339.39
-
Formule C22H17N3O
-
Color Light yellow to yellow
-
SMILES
O=C1N(CC2=CC=CC=C2)C(/C=C/C3=CC=CN=C3)=NC4=C1C=CC=C4
-
Synonyms
B02
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (16)
-
Journal Impact Factor
-
Most Recent
-
Cell
Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601 -
Drug Resist Updat
Centromere protein U mediates the ubiquitination and degradation of RPS3 to facilitate temozolomide resistance in glioblastoma. [Abstract]2025 May:80:101214. PMID: 40023134 -
Nat Commun
2025 Jan 27;16(1):1077. PMID: 39870664
RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 27;16(1):1077. [Abstract]
Response of lung and breast cell line models to DNA-PK inhibition (NU7441) and RAD51 (RAD51 Inhibitor B02 (B02, 0-100 μM, 72 h)) inhibition. Cells were irradiated with 2 Gy and treated with each small-molecule for 72h. Cell viability relative to DMSO control was assessed in a CellTiterGlo luminescence assay.
-
Cancer Lett
N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer. [Abstract]2023 Apr 1:558:216092. PMID: 36806557 -
Cancer Lett
Inhibition of the DSB repair protein RAD51 potentiates the cytotoxic efficacy of doxorubicin via promoting apoptosis-related death pathways. [Abstract]2021 Nov 1:520:361-373. PMID: 34389435 -
Oncogene
LncRNA CACClnc promotes chemoresistance of colorectal cancer by modulating alternative splicing of RAD51. [Abstract]2023 Apr;42(17):1374-1391. PMID: 36906654
RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Oncogene. 2023 Apr;42(17):1374-1391. [Abstract]
RAD51 Inhibitor B02 (2 μM; 48 h) increases sensitivity of HT29 cells to Oxaliplatin or 5-FU.
-
-
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Cancers (Basel)
CD81 Enhances Radioresistance of Glioblastoma by Promoting Nuclear Translocation of Rad51. [Abstract]2021 Apr 21;13(9):1998. PMID: 33919192
RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2021 Apr 21;13(9):1998. [Abstract]
U251R and T98G Cells were treated with RAD51 Inhibitor B02 (B02, 10 μM), its control (1‰ DMSO), or B02 + siCD81 and then irradiated with X-rays. Representative immunostaining images (left) and quantification (right) of nuclear Rad51 foci in the cells at 2 h after 6 Gy irradiation. Blue, DAPI stained nuclear. Red, Rad51 foci.
RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2021 Apr 21;13(9):1998. [Abstract]
U251R and T98G Cells were treated with RAD51 Inhibitor B02 (B02, 10 μM), its control (1‰ DMSO), or B02 + siCD81 and then irradiated with X-rays. Western blot assay (left) and quantitation (right) of cytoplasmic (cyto) and nuclear (nuc) proteins of Rad51 level and CD81 at 2 h after 6 Gy irradiation.
RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2021 Apr 21;13(9):1998. [Abstract]
U251R and T98G Cells were treated with RAD51 Inhibitor B02 (B02, 10 μM), its control (1‰ DMSO), or B02 + siCD81 and then irradiated with X-rays. Representative immunostaining images (left) and quantification (right) of γ-H2AX foci in the cells at 2 h after 6 Gy irradiation. Blue, DAPI stained nuclear. Red, γ-H2AX foci.
RAD51 Inhibitor B02 purchased from MedChemExpress. Usage Cited in: Cancers (Basel). 2021 Apr 21;13(9):1998. [Abstract]
U251R and T98G Cells were treated with B02 (10 μM), its control (1‰ DMSO), or B02 + siCD81 and then irradiated with X-rays. Clonogenic survivals of X-ray irradiated U251R and T98G cells under different treatment of B02 or B02 + siCD81.
-
Cell Signal
Gastric cancer derived mesenchymal stem cells promoted DNA repair and cisplatin resistance through up-regulating PD-L1/Rad51 in gastric cancer. [Abstract]2023 Jun:106:110639. PMID: 36842523 -
Discov Oncol
RAD51 modulates in nasopharyngeal carcinoma cells by regulating Caspase-8-mediated pyroptosis. [Abstract]2025 Jul 12;16(1):1320. PMID: 40650821 -
J Cancer Res Ther
Berberine enhances the radiosensitivity of osteosarcoma by targeting Rad51 and epithelial-mesenchymal transition. [Abstract]2020;16(2):215-221. PMID: 32474504 -
bioRxiv
2025 Jun 17:2025.06.16.659978. PMID: 40667017 -
-
-
Res Sq
Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells. [Abstract]2023 Apr 6:rs.3.rs-2688694. PMID: 37066268
Solvant et solubilité
DMSO : ≥ 37 mg/mL (109.02 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 20% DMSO 20% Cremophor EL 60% Saline
Solubility: 10 mg/mL (29.46 mM); Clear solution; Need ultrasonic
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (5.89 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
The cells are exposed for 1 h, then the cells are ished by PBS three times and refreshed by the media containing B02 (5 µM). After 7-10 days, cells are fixed and stained with staining solution (0.05% crystal violet, 50% methanol in PBS); finally cell colonies are counted[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: Cisplatin and B02 are dissolved in NS and cremophor/DMSO/NS (1:1:3) vehicle, respectively, immediately before injection. In a combination treatment group, the mice are injected with B02 (50 mg/kg or indicated otherwise) and cisplatin (4 mg/kg or indicated otherwise). In B02 group, mice are injected with B02 and NS; in cisplatin group, mice are injected with cisplatin and B02 vehicle. Cisplatin (or NS) is administrated 3 h after B02 (or its vehicle) injection. All the treatments are executed through I.P. injections on day 11, 13, 15 and 17 after tumor cells inoculations[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Huang F, et al. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol. 2011 Jun 17;6(6):628-35. [Content Brief]
[2]. Huang F, et al. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS One. 2014 Jun 27;9(6):e100993. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9465 mL | 14.7323 mL | 29.4646 mL | 73.6616 mL |
| 5 mM | 0.5893 mL | 2.9465 mL | 5.8929 mL | 14.7323 mL | |
| 10 mM | 0.2946 mL | 1.4732 mL | 2.9465 mL | 7.3662 mL | |
| 15 mM | 0.1964 mL | 0.9822 mL | 1.9643 mL | 4.9108 mL | |
| 20 mM | 0.1473 mL | 0.7366 mL | 1.4732 mL | 3.6831 mL | |
| 25 mM | 0.1179 mL | 0.5893 mL | 1.1786 mL | 2.9465 mL | |
| 30 mM | 0.0982 mL | 0.4911 mL | 0.9822 mL | 2.4554 mL | |
| 40 mM | 0.0737 mL | 0.3683 mL | 0.7366 mL | 1.8415 mL | |
| 50 mM | 0.0589 mL | 0.2946 mL | 0.5893 mL | 1.4732 mL | |
| 60 mM | 0.0491 mL | 0.2455 mL | 0.4911 mL | 1.2277 mL | |
| 80 mM | 0.0368 mL | 0.1842 mL | 0.3683 mL | 0.9208 mL | |
| 100 mM | 0.0295 mL | 0.1473 mL | 0.2946 mL | 0.7366 mL |
RAD51 Inhibitor B02 Related Classifications
HY-101462 Related Classifications
Powered by Bioz